- In this clinical first for adults with heart failure with preserved ejection fraction, empagliflozin demonstrated an impressive 21 percent relative risk reduction in the composite primary endpoint of cardiovascular death or hospitalization for heart failure1
- The benefit in the primary endpoint was independent of ejection fraction or diabetes status1
- Empagliflozin also reduced the relative risk of first and recurrent hospitalizations for heart failure by 27 percent and significantly slowed kidney function decline1
- Results from the Phase III EMPEROR-Preserved trial were presented today at the European Society of Cardiology Congress 20212 and published in The New England Journal of Medicine1
INGELHEIM, Germany & INDIANAPOLIS-Saturday 28 August 2021 [ AETOS Wire ]
(BUSINESS WIRE) -- Full results from the landmark EMPEROR-Preserved Phase III trial demonstrated that empagliflozin showed an impressive 21 percent relative ri
...
Read more »